Literature DB >> 15459335

Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity.

Cécile Buhot1, Alexandre Chenal, Alain Sanson, Sandra Pouvelle-Moratille, Michael H Gelb, André Ménez, Daniel Gillet, Bernard Maillère.   

Abstract

We have engineered a recombinant form of the major bee venom allergen (Api m 1) with the final goal of reducing its IgE reactivity. This molecule (Api mut) contains 24 mutations and one deletion of 10 amino acids. The successive introduction of these sequence modifications led to a progressive loss of specific IgE and IgG reactivity and did not reveal any immunodominant epitopes. However, Api mut exhibited a clear loss of reactivity for Api m 1-specific IgE and IgG. Injection of Api mut into mice induced specific antibody production. This humoral response was as high as that induced by the Api m 1 but the cross-reactivity of the antibodies was weak. As inferred by far UV circular dichroism, this mutant was correctly folded. However, near UV circular dichroism and denaturation curves of Api mut showed that it exhibits a dynamic tertiary structure and that it is a highly flexible molecule. Finally, as all the sequence modifications have been introduced outside the human and murine T cell epitope regions, we investigated its T cell properties in mice. We showed that Api mut-specific T lymphocytes induced in vivo were stimulated in vitro by both proteins. These data provide new insights in the design of hypoallergenic molecules.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15459335      PMCID: PMC2286571          DOI: 10.1110/ps.04885404

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  34 in total

1.  On the diversity and heterogeneity of H-2(d)-restricted determinants and T cell epitopes from the major bee venom allergen.

Authors:  C Texier; M Hervé; S Pouvelle; A Ménez; B Maillère
Journal:  Int Immunol       Date:  1999-08       Impact factor: 4.823

2.  Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo.

Authors:  Anette Sundstedt; Emma J O'Neill; Kirsty S Nicolson; David C Wraith
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

3.  High-level expression in Escherichia coli and rapid purification of enzymatically active honey bee venom phospholipase A2.

Authors:  T Dudler; W Q Chen; S Wang; T Schneider; R R Annand; R O Dempcy; R Crameri; M Gmachl; M Suter; M H Gelb
Journal:  Biochim Biophys Acta       Date:  1992-12-02

4.  Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10.

Authors:  C Burkhart; G Y Liu; S M Anderton; B Metzler; D C Wraith
Journal:  Int Immunol       Date:  1999-10       Impact factor: 4.823

5.  Circular dichroism and optical rotatory dispersion of proteins and polypeptides.

Authors:  A J Adler; N J Greenfield; G D Fasman
Journal:  Methods Enzymol       Date:  1973       Impact factor: 1.600

6.  Sensitive quantitative analysis of disulfide bonds in polypeptides and proteins.

Authors:  T W Thannhauser; Y Konishi; H A Scheraga
Journal:  Anal Biochem       Date:  1984-04       Impact factor: 3.365

7.  Allergens of honey bee venom.

Authors:  T P King; A K Sobotka; L Kochoumian; L M Lichtenstein
Journal:  Arch Biochem Biophys       Date:  1976-02       Impact factor: 4.013

8.  Structural analysis of phospholipase A2 from functional perspective. 2. Characterization of a molten globule-like state induced by site-specific mutagenesis.

Authors:  C Yuan; I J Byeon; M J Poi; M D Tsai
Journal:  Biochemistry       Date:  1999-03-09       Impact factor: 3.162

9.  Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue.

Authors:  D L Scott; Z Otwinowski; M H Gelb; P B Sigler
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

10.  Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.

Authors:  U Müller; A Helbling; E Berchtold
Journal:  J Allergy Clin Immunol       Date:  1992-02       Impact factor: 10.793

View more
  6 in total

Review 1.  Hymenoptera venom allergens.

Authors:  Donald R Hoffman
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

2.  A reduced amino acid alphabet for understanding and designing protein adaptation to mutation.

Authors:  C Etchebest; C Benros; A Bornot; A-C Camproux; A G de Brevern
Journal:  Eur Biophys J       Date:  2007-06-13       Impact factor: 1.733

Review 3.  Structural characterization of pollen allergens.

Authors:  Petra Verdino
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

Review 4.  Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.

Authors:  Birgit Linhart; Rudolf Valenta
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

5.  Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1.

Authors:  Christine Almunia; Marie Bretaudeau; Gerhard Held; Aurélie Babon; Charles Marchetti; Florence Anne Castelli; André Ménez; Bernard Maillere; Daniel Gillet
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

Review 6.  Genetically engineered vaccines.

Authors:  Wayne R Thomas; Belinda J Hales; Wendy-Anne Smith
Journal:  Curr Allergy Asthma Rep       Date:  2005-05       Impact factor: 4.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.